|
VDAC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
7.8599000000068E-05 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.618840E-03 |
| Stage1-vs-Stage3 |
1.283780E-01 |
| Stage1-vs-Stage4 |
4.83520000038595E-07 |
| Stage2-vs-Stage3 |
1.805070E-04 |
| Stage2-vs-Stage4 |
7.98760000364496E-08 |
| Stage3-vs-Stage4 |
5.062200E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.21340001882453E-09 |
| Normal-vs-Asian |
1.62436730732907E-12 |
| Caucasian-vs-AfricanAmerican |
9.770800E-01 |
| Caucasian-vs-Asian |
5.230800E-01 |
| AfricanAmerican-vs-Asian |
6.786000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.607800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
5.95079541199084E-14 |
| Normal-vs-Age(81-100Yrs) |
9.84910000223493E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.362800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.766400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.641200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.691620E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.950000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.316200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.68589999925007E-08 |
| Classical-VS-Follicular |
2.3259172365897E-13 |
| Classical-VS-Other |
8.210600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.62447832963153E-12 |
| Tall-VS-Other |
1.963800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.615900E-02 |
| Follicular-VS-Normal |
1.3867000003831E-07 |
| Other-VS-Normal |
1.99030000036515E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.39053221662289E-12 |
|
|
